Michael Gelband’s BeOne Medicines Ltd ONC Stock Holding History

Michael Gelband’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,980	Closed	-$3.26M	–	2188
2026 Q1	$3.26M	Sell	10,980 -13,604	-55%	-$4.4M	0.03%	589
2025 Q4	$7.47M	Buy	24,584 +14,651	+147%	+$4.8M	0.06%	337
2025 Q3	$3.38M	Sell	9,933 -4,973	-33%	-$1.51M	0.03%	550
2025 Q2	$3.61M	Buy	+14,906	New	+$3.66M	0.03%	522
2024 Q4	–	Sell	-13,600	Closed	-$3.05M	–	2165
2024 Q3	$3.05M	Sell	13,600 -21,675	-61%	-$3.9M	0.02%	582
2024 Q2	$5.03M	Buy	35,275 +17,104	+94%	+$2.64M	0.03%	401
2024 Q1	$2.84M	Buy	+18,171	New	+$2.93M	0.02%	578
2021 Q3	–	Sell	-19,442	Closed	-$6.67M	–	2745
2021 Q2	$6.67M	Buy	+19,442	New	+$6.44M	0.07%	252
2020 Q4	–	Sell	-4,113	Closed	-$1.18M	–	2458
2020 Q3	$1.18M	Sell	4,113 -2,941	-42%	-$691K	0.02%	614
2020 Q2	$1.33M	Buy	+7,054	New	+$1.15M	0.03%	603

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's ONC Position: Q2 2026 in Review

Michael Gelband sold out of BeOne Medicines Ltd (ONC) in Q2 2026, closing a stake of 10,980 shares — an estimated $3.26M sold.

Michael Gelband first reported a position in ONC in Q2 2020 and held it in 10 quarters. The position peaked at $7.47M in Q4 2025. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Michael Gelband reported no remaining BeOne Medicines Ltd position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 10,980 BeOne Medicines Ltd shares in Q2 2026, an estimated $3.26M.
Michael Gelband first reported a position in BeOne Medicines Ltd in Q2 2020 and held it in 10 quarters.
Michael Gelband's BeOne Medicines Ltd position peaked at $7.47M in Q4 2025.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.